iSpecimen (ISPC) Cash & Equivalents (2020 - 2026)

iSpecimen's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 260.23% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 260.23% YoY), while the FY2025 annual figure was $6.9 million, up 266.31% from the prior year.
• Cash & Equivalents was $2.8 million for Q1 2026 at iSpecimen, down from $6.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $26.1 million in Q1 2022 to a low of $588775.0 in Q2 2025.
• Historically, Cash & Equivalents has averaged $7.0 million across 5 years, with a median of $2.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 91.54% in 2023, then jumped 266.31% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $15.3 million in 2022, then sank by 84.69% to $2.3 million in 2023, then decreased by 19.85% to $1.9 million in 2024, then surged by 266.31% to $6.9 million in 2025, then slumped by 59.03% to $2.8 million in 2026.
• The last three Cash & Equivalents figures came in at $2.8 million (Q1 2026), $6.9 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.